Opendata, web and dolomites


Development of RGD-therapeutics for cardio-metabolic disease

Total Cost €


EC-Contrib. €






 RGD-Diabetes project word cloud

Explore the words cloud of the RGD-Diabetes project. It provides you a very rough idea of what is the project "RGD-Diabetes" about.

vivo    electrostatic    muscle    profiling       secretion    molecule    atherosclerosis    intolerance    macrovascular    consistently    disease    living    igfbp1    circulating    therapeutic    stimulated    therapeutically    proof    surface    domain    ectodomain    mortality    exploited    analogues    starting    commercialisation    cells    commonest    pressure    pipeline    insulin    interaction    progressed    pharmaceutical    matching    vascular    anticipate    industry    small    possesses    quality    igf    rgd    translation    integrin    sensitisation    throughput    idea    designing    vitro    islets    adme    commercially    agonists    glucose    structures    pancreatic    failed    contingency    million    skeletal    schemes    screening    first    innovation    ligands    risk    blood    people    virtual    discovery    therapies    grant    therapeutics    library    validate    alpha    lowering    drug    events    morbidity    reduce    protein    binding    repair    mediated    beta    discovered    amelioration    subsequently    molecules    receptors    mimics    hence    hits    58    too    36    cardiovascular    bind    diabetes    carry    shape    predicted    silico    me    cell   

Project "RGD-Diabetes" data sheet

The following table provides information about the project.


Organization address
city: LEEDS
postcode: LS2 9JT

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF LEEDS UK (LEEDS) coordinator 150˙000.00


 Project objective

In Europe, 58 million people are living with type 2 diabetes and 36 million people are at risk of developing the condition. Macrovascular disease is the commonest cause of morbidity and mortality in type 2 diabetes, yet current diabetes therapies have failed to consistently reduce cardiovascular events. In my Starting Grant, I discovered that a circulating protein, IGF binding protein-1, possesses several favourable characteristics– including insulin sensitisation, amelioration of glucose intolerance, blood pressure lowering, reduced atherosclerosis and increased vascular repair. These effects are mediated by interaction of the protein’s RGD-domain with cell-surface α5β1 integrin receptors, which increases insulin-stimulated glucose uptake in skeletal muscle cells and glucose-stimulated insulin secretion in pancreatic islets. Hence the ‘idea’ from my Starting Grant is that RGD-integrin interaction could be exploited therapeutically in diabetes. In this Proof-of-Concept grant, we will take the first step towards commercialisation of the idea by designing and testing small molecule mimics of the RGD domain of IGFBP1 as diabetes therapeutics. Using in silico modelling based on the known structures of IGFBP1 and the α5β1 integrin ectodomain, we will design a small molecule library of commercially available potential agonists. We will carry out virtual high throughput screening of the library for molecules matching the shape and electrostatic potential of the RGD domain of IGFBP1 as predicted to bind to α5β1 integrin. As contingency, we will also identify in silico ‘me-too’ analogues of known integrin ligands. We will test the best quality hits through ADME profiling and validate therapeutic activity in vitro and in vivo. At the end of the project, we anticipate we will have identified small molecule RGD mimics which can subsequently be progressed through the drug-discovery pipeline through translation grant funding or pharmaceutical industry Open Innovation schemes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RGD-DIABETES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RGD-DIABETES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ImmUne (2019)

Towards identification of the unifying principles of vertebrate adaptive immunity

Read More  

ZARAH (2020)

Women’s labour activism in Eastern Europe and transnationally, from the age of empires to the late 20th century

Read More  

SiMS (2019)

Simulated Majorana states

Read More